SCHEMBL396368

SCHEMBL396368

Cc1ccc(-c2cn3cc(C)ccc3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 1.00
RAB9A P51151 11/20 1.00
ALDH1A1 P00352 11/20 1.00
KDM4E B2RXH2 10/20 1.00
SMN1; SMN2 Q16637 9/20 1.00
KMT2A Q03164 3/20 1.00
PAX8 Q06710 2/20 1.00
MEN1 O00255 1/20 1.00
MITF O75030 1/20 1.00
KDM5A P29375 1/20 1.00
KDM5C P41229 1/20 1.00
APP P05067 2/20 0.80
HPGD P15428 6/20 0.77
PKM P14618 4/20 0.77
TP53 P04637 3/20 0.77
HSD17B10 Q99714 3/20 0.77
TSHR P16473 1/20 0.77
CDK5 Q00535 1/20 0.77
CDK5R1 Q15078 1/20 0.77
ALDH1A3 P47895 4/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13325772 0.90 ALDH1A3 (0.87) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1691254 0.89 NPC1 (0.80) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL10120370 0.89 NPC1 (0.80) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL13325747 0.89 NPC1 (0.90) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1691890 0.89 ALDH1A3 (0.82) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1691247 0.89 NPC1 (0.80) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1983316 0.89 NPC1 (0.80) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL973527 0.89 NPC1 (1.00) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL21708016 0.89 NPC1 (0.80) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1987470 0.89 NPC1 (0.96) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380819-B Zolpidem intermediate compounds 鲁南制药集团股份有限公司 2024-08-23 CN claimed
CN-116768884-A Method for synthesizing zolpidem 湖南大学 2023-09-19 CN claimed
CN-114892188-A Method for electrochemically synthesizing zolpidem 江苏农牧科技职业学院 2022-08-12 CN claimed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
US-8183377-B2 Process for the preparation of imidazopyridines ELDER PHARMACEUTICALS LTD. 2012-05-22 US claimed
EP-1917263-B1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES ELDER PHARMACEUTICALS LTD (IN) 2010-11-24 EP claimed
US-20100036129-A1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES ELDER PHARMACEUTICALS LTD. (IN) 2010-02-11 US claimed
WO-2009007995-A1 PROCESS FOR PREPARING ZOLPIDEM AND ITS INTERMEDIATE SUVEN LIFE SCIENCES LIMITED (IN) 2009-01-15 WO claimed
US-20080293947-A1 Method of Preparation for Imidazolepyridines MALLINCKRODT INC. 2008-11-27 US claimed
US-6861437-B2 Substituted imidazo [1,2-a] pyridine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-01 US claimed
EP-1381363-B1 IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2004-12-08 EP claimed
US-20040180921-A1 Substituted imidazo[1,2-a]pyridine derivatives MUTEL VINCENT (FR) 2004-09-16 US claimed
EP-1381363-A1 IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-01-21 EP claimed
US-20030212096-A1 Substituted imidazo [1,2-a] pyridine derivatives MUTEL VINCENT (FR) 2003-11-13 US claimed
EP-1104765-B1 PROCESS FOR PREPARING N,N,6- TRIMETHYL-2 -(4-METHYLPHENYL)- IMIDAZO-[1,2-A] -PYRIDINE-3- ACETAMIDE AND SALTS THEREOF SINT QUIMICA SA (ES) 2003-03-19 EP claimed
US-20020188128-A1 Substituted imidazo[1,2-A] pyridine derivatives F.HOFFMANN-LA ROCHE AG (CH) 2002-12-12 US claimed
WO-2002092086-A1 IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-11-21 WO claimed
US-6407240-B1 REDUCTION OF THE CORRESPONDING ESTER; REACTING WITH IMINIUM SALT QUIMICA SINTETICA, S.A. (ES) 2002-06-18 US claimed
EP-1104765-A2 PROCESS FOR PREPARING N,N,6- TRIMETHYL-2 -(4-METHYLPHENYL)- IMIDAZO- 1,2-A] -PYRIDINE-3- ACETAMIDE AND SALTS THEREOF Quimica Sintetica, S.A. (ES) 2001-06-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212096-A1 Substituted imidazo [1,2-a] pyridine derivatives GRM5, GRM1, GRIK5 NPC1 413/4885RAB9A 982/4885ALDH1A1 1154/4885
US-20080293947-A1 Method of Preparation for Imidazolepyridines ITPA, QDPR, NISCH NPC1 4098/4885RAB9A 3568/4885ALDH1A1 841/4885
US-20100036129-A1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES OTC, ODC1, OGDH NPC1 3053/4885RAB9A 2279/4885ALDH1A1 384/4885
US-20040180921-A1 Substituted imidazo[1,2-a]pyridine derivatives GRM5, GRM1, GRIK5 NPC1 413/4885RAB9A 982/4885ALDH1A1 1154/4885
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A NPC1 4209/4885RAB9A 3350/4885ALDH1A1 187/4885
US-20020188128-A1 Substituted imidazo[1,2-A] pyridine derivatives GRM5, GRM1, GRIK5 NPC1 413/4885RAB9A 982/4885ALDH1A1 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.